TransCode Therapeutics announces 1 for 40 reverse stock split

Nishadil
January 11, 2024
0 Comments
0.25 minutes read
5 Views

TransCode Therapeutics ( NASDAQ: RNAZ ) on Thursday announced that its Board of Directors has approved a 1 for 40 reverse stock split, to be effective on January 16, 2024. TransCode common stock is expected to begin trading on a split adjusted basis on Nasdaq under the current trading symbol, “RNAZ.” RNAZ +1.62% premarket to $0.125. Source: Press Release More on TransCode Therapeutics TransCode Therapeutics announces $1.2M registered direct offering of common stock TransCode shares plunge 20% on stock offering, Nasdaq compliance update Seeking Alpha’s Quant Rating on TransCode Therapeutics

Blockchain Technology in Healthcare Market to increase USD 750 billion by 2033 | Public network types to be the major contributing segment

Nektar Therapeutics expects cash runway into at least mid 2026

Aclaris draws second downgrade despite Phase 2 win for eczema therapy

Nearly 10K died from COVID 19 last month: WHO says

Praxis Precision Medicines falls after pricing of $150M equity offering

Eric Adams’s constitutionally dubious busing lawsuit is a political sideshow

Time for President Biden to follow 'The Gipper' and invoke the Reagan Doctrine against Iran